Since its inception in 1980, the Sidney Kimmel Comprehensive Cancer Center (SKCCC) Flow Cytometry Shared Resource has continuously offered state-of-the art cell sorting and analysis capabilities to the members of the SKCCC. These services are provided in a timely, flexible and affordable manner to Cancer Center members from across the entire medical campus. The resources provided by the Flow Core are not a duplication of those available elsewhere, and range from basic two color analyses, to complex sorting experiments involving up to 14 colors and 16 discrete parameters. Since the last renewal, the Flow Core has undergone the most dramatic update in its history. Specifically, the Core has acquired several new instruments, including two new high-end sorters. Both of these are high-speed, 14 color / 16 parameter Facs Aria units. The second unit is housed in a custom BSL-3 BioPROtect 111 Bio-Containment Enclosure, permitting users to sort un-fixed human cells under applicable CDC guidelines. The Core has also been relocated to a new, custom-designed physical space, a 1400 square ft. suite of three rooms on the fourth floor of the SKCCC Cancer Research Building (CRBI). Also, a new analysis unit, a special order research platform (SORP) LSR-II, with enhanced flow rates and detection capabilities has been added. Perhaps most significantly, two new experienced and dedicated personnel have been hired. Ms. Ada Tam serves as the Resource Manager;and Mr. Richard (Lee) Blosser who serves as co-manager and training Director. Their respective roles will be further detailed below. However, it should be noted that the Core now has the resources to provide training on each of the analysis units, cell sorting services, as well as back-end analysis assistance. Lay: Flow cytometry, is a method of sorting and measuring types of cells by fluorescent labeling of markers on the surface of the cells. It is sometimes referred to as FACS (Fluorescent Activated Cell Sorting) analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-50
Application #
8559741
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
50
Fiscal Year
2013
Total Cost
$168,740
Indirect Cost
$64,580
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225

Showing the most recent 10 out of 2393 publications